CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 34 enrolled
Drug / intervention
Cabozantinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03586973
NCT03586973Phase 2Completed
CompareCT.gov

A Phase 2, Open-Label, Single-Arm Study of Cabozantinib in Japanese Patients With Advanced Hepatocellular Carcinoma Who Have Received Prior Systemic Anticancer Therapy

Takeda·interventional·Posted Jul 16, 2018·Updated Apr 18, 2023

In Brief

A Phase 2 clinical trial evaluating Cabozantinib for Advanced Hepatocellular Carcinoma. Completed, enrolled 34 participants across 17 sites.

Detailed Summary

The purpose of this study is to evaluate the efficacy and safety of cabozantinib in Japanese participants with advanced hepatocellular carcinoma (HCC) who have received prior systemic anticancer therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Hepatocellular Carcinoma
CountriesJapan
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJul 16, 2018
Enrollment StartAug 6, 2018
Primary CompletionJul 17, 2019
Study CompletionJun 29, 2021
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 8.0 years ago

Interventions

Cabozantinibdrug

Cabozantinib tablet